Literature DB >> 2090472

Bronchial response to nebulized antibiotics in children with cystic fibrosis.

H L Chua1, G G Collis, P N Le Souëf.   

Abstract

Nebulized antibiotics are being used increasingly in children with cystic fibrosis. We assessed the effect of nebulized antibiotic solutions of varying tonicity on lung function in 12 children aged 5-15 yrs with cystic fibrosis. Baseline forced expiratory volume in one second and (FEV1) was measured, followed by a single nebulization of normal saline (272 mosmol.kg-1), tobramycin (248 mosmol.kg-1), or ticarcillin (3,080 mosmol.kg-1). All children received each of these, administered randomly, one per day. FEV1 was remeasured 5, 15 and 30 min after completion of the nebulization. Ticarcillin (mean fall 10.7% (SD 8.9)) caused a larger fall in FEV1 than normal saline (4.8% (4.3), p less than 0.05). The fall in FEV1 for ticarcillin was greater than for tobramycin (1.2% (2.0), p less than 0.05). Normal saline did not result in a significantly larger fall in FEV1 than tobramycin (p greater than 0.05). Bronchoconstriction to ticarcillin persisted at 30 min. We conclude that nebulized antibiotics can affect lung function in children with cystic fibrosis if the solutions are hypertonic.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2090472

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  14 in total

1.  Bronchoconstriction following nebulised colistin in cystic fibrosis.

Authors:  S Cunningham; A Prasad; L Collyer; S Carr; I B Lynn; C Wallis
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

2.  Comparison of lung deposition of colomycin using the HaloLite and the Pari LC Plus nebulisers in patients with cystic fibrosis.

Authors:  N M Byrne; P M Keavey; J D Perry; F K Gould; D A Spencer
Journal:  Arch Dis Child       Date:  2003-08       Impact factor: 3.791

Review 3.  Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia.

Authors:  G Christopher Wood; Joseph M Swanson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Bronchoprovocation testing.

Authors:  Chakravarthy Reddy
Journal:  Clin Rev Allergy Immunol       Date:  2009-03-17       Impact factor: 8.667

5.  Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis.

Authors:  W H Nikolaizik; V Jenni-Galović; M H Schöni
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

Review 6.  Aerosol antibiotic treatment in cystic fibrosis.

Authors:  J M Littlewood; S W Smye; H Cunliffe
Journal:  Arch Dis Child       Date:  1993-06       Impact factor: 3.791

7.  Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis.

Authors:  M E Dodd; J Abbott; J Maddison; A J Moorcroft; A K Webb
Journal:  Thorax       Date:  1997-07       Impact factor: 9.139

8.  Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis.

Authors:  Kate H Regan; Jayesh Bhatt
Journal:  Cochrane Database Syst Rev       Date:  2019-04-18

Review 9.  Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.

Authors:  Sherie Smith; Nicola J Rowbotham; Edward Charbek
Journal:  Cochrane Database Syst Rev       Date:  2022-08-01

Review 10.  Nebulized antibiotics in cystic fibrosis.

Authors:  Isabelle Sermet-Gaudelus; Yann Le Cocguic; Agnés Ferroni; Marlène Clairicia; Joel Barthe; Jan-Pierre Delaunay; Valentine Brousse; Gérard Lenoir
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.